^
    Back
    Association details:
    Biomarker:FLT3 N676K
    Cancer:Acute Myelogenous Leukemia
    Drug:Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Rinsho Ketsueki
    Title:

    Successful treatment with gilteritinib for relapsed acute myeloid leukemia with FLT3-N676K mutation

    Published date:
    02/08/2022
    Excerpt:
    Comprehensive genetic analysis revealed a FLT3-N676K mutation that could not be detected by current companion diagnostics. Gilteritinib monotherapy was started, and the swelling of the lips and gingiva improved markedly, and CRi was obtained on the 28th day.
    DOI:
    https://doi.org/10.11406/rinketsu.63.51